One of the more serious concerns the FDA has discussed is the possibility that a developer of a proposed biosimilar could be deterred from seeking approval of its product, because United States Pharmacopeial Convention's (USP) proposed changes could complicate the licensure of a proposed biosimilar that meets the approval requirements of the FDA but does not match the USP’s standards of a monograph.
Yesterday, Peter Marks, MD, and Janet Woodcock, MD, directors of the Center for Biologics Evaluation and Research at the FDA, sent a letter to the United States Pharmacopeial Convention (USP) in response to its request for comments regarding its recently proposed revisions to drug product monographs for biologic medicines.
The letter, addressed to Ronald Piervincenzi, PhD, CEO of USP, thanked USP for the opportunity comment, but addressed serious concerns the FDA has about the potential consequences of the proposed revisions.
Under the Social Security Act, the Medicare program provides reimbursement for medical and other health services including drugs and biologics. In 1980, the USP Convention determined that the USP should attempt to include monographs for all drug entities and products marketed in the United States, which led to all drugs approved by the FDA being eligible for inclusion.
In September 2017, USP issued a Notice of Intent to Revise, which proposed the following change to its Official Articles of the General Notices and Requirements:
“For a biologic product licensed under the Public Health Service Act, the official title shall be the title specified in the relevant monograph plus any suffix designated by the FDA unless otherwise specified in the applicable monograph.”
In a previous letter to USP in 2014, the FDA noted concerns that monographs for biologics could inhibit or delay innovative technology and could be seen as an additional burden on regulated industry. In this letter, the FDA suggested that USP develop optional standards that are “consistent with the flexible approach FDA uses to properly account for the complex nature of biological products.”
“We understand that USP’s proposed revisions are intended to harmonize its approach to biological product monographs with the policy described in FDA’s guidance for industry, ‘Nonproprietary Naming of Biological products,’” read the letter.
The FDA’s naming guidance states that the nonproprietary name for each originator biologic, related biologic, and biosimilar product will be a combination of the core name followed by a 4-letter suffix devoid of meaning.
One of the more serious concerns the FDA has discussed is the possibility that a developer of a proposed biosimilar could be deterred from seeking approval of its product, because USP’s proposed changes could complicate the licensure of a proposed biosimilar that meets the approval requirements of the FDA but does not match the USP’s standards of a monograph.
“FDA is committed to supporting a robust marketplace of biological products that provide innovative, accessible, therapeutic options to patients,” said the letter. “The timely licensure of biosimilar and interchangeable products is essential to achieving greater price competition in this marketplace, which can help bring down the costs of biological products. Thus, any delay in licensure of biosimilar or interchangeable products could cause these potential savings to consumers and the healthcare system to be lost.”
Though the FDA ultimately encouraged USP to withdraw its proposed revisions, Marks and Woodcock said that that they welcome future interaction and discussions with USP on these issues.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.